Targeted therapy of inflammatory bowel diseases: realities and prospects

This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases. It presents the data of the latest randomized clinical trials and meta-analyses evaluating the efficacy and safety of targeted drugs for the treatment of Crohn’s disease and ulcerative colitis.

1. Bruining DH. Inflammatory Bowel Disease: Clinical Aspects. In.: Mayo Clinic Gastroentero-logy and Hepatology Board Review. NY, 2015.

2. Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care, 2017, 44(4): 673-692.

3. Guide on Internal Medicine. Edited by Arutyunova GP, Martynova AI, Spassky AA. M., 2015.

4. Maev IV, Andreev DN, Dicheva DT, Velikanov EV. Crohn’s disease: etiopathogenesis, diagnosis and conservative treatment. M., 2016.

5. Osterman MT, Lichtenstein GR. Ulcerative Colitis. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. 10th ed. 2015.

6. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol, 2015, 50(8): 942-51.

7. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, 2017 Oct 13. pii: S0140-6736(17)32448-0.

8. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol, 2015, 12(4): 205-17.

9. Ye Y, Pang Z, Chen W, et al. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med, 2015, 8(12): 22529-42.

10. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology, 2008, 135(5): 1442-7.

11. Bai A, Peng Z. Biological therapies of inflammatory bowel disease. Immunotherapy, 2010, 2(5): 727-42.

12. Uniken Venema WT, Voskuil MD, Dijkstra G, Weersma RK, Festen EA. The genetic background of inflammatory bowel disease: from correlation to causality. J Pathol, 2017, 241(2): 146-158.

13. Hall AB, Tolonen AC, Xavier RJ. Human genetic variation and the gut microbiome in disease. Nat Rev Genet, 2017, 18(11): 690-699.

14. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol, 2017, 14(10): 573-584.

15. Maev IV, Andreev DN. Molecular genetic mechanisms of development of Crohn’s disease. Molekulyarnaya Meditsina, 2014, 3: 21-27.

16. Bank S, Skytt Andersen P, Burisch J, et al. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PLoS One, 2014 Jun 27, 9(6): e98815.

17. Maev IV, Andreev DN. Role of mutations in NOD2/CARD15, ATG16L1, and IRGM in the pathogenesis of Crohn’s disease. International Journal of Biomedicine, 2014, 4(1): 7-10.

18. Loddo I, Romano C. Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis. Front Immunol, 2015, 6: 551

19. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science, 2006, 314(5804): 1461–1463.

20. Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn’s disease. Discov Med, 2012, 14(77): 253-62.

21. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol, 2014, 20(5): 1192-210.

22. Øyri SF, Műzes G, Sipos F. Dysbiotic gut microbiome: A key element of Crohn’s disease. Comp Immunol Microbiol Infect Dis, 2015 Dec, 43: 36-49.

23. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol, 2015, 179(3): 363-77.

24. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol, 2012, 13(9): R79.

25. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe, 2014, 15(3): 382-92.

26. Martinez-Medina M, Garcia-Gil LJ. Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol, 2014, 5(3): 213-27.

27. Maev IV, Andreev DN, Rakitina DV, Baikova YuP. The role of autophagy defects and the importance of adherent-invasive Escherichia coli in the Crohn’s disease genesis. RZHGGK, 2015, 3: 61-69.

28. Rakitina DV, Manolov AI, Kanygina AV, et al. Genome analysis of E. coli isolated from Crohn’s disease patients. BMC Genomics, 2017, 18(1): 544.

29. Palmela C, Chevarin C, Xu Z, et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut, 2017 Nov 15. pii: gutjnl-2017-314903.

30. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis, 2014, 8(12): 1569-81.

31. Narula N, Kassam Z, Yuan Y, et al. Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis, 2017, 23(10): 1702-1709.

32. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol, 2015, 8(2): 66-82.

33. Маев И.В., Андреев Д.Н. Новые подходы к диагностике и лечению болезни Крона. Тер архив, 2014, 8: 4-12./ Maev IV, Andreev DN. New approaches to the diagnosis and treatment of Crohn’s disease. Ter arkhiv, 2014, 8: 4-12.

34. Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opin Investig Drugs, 2016, 25(2): 129-43.

35. Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol, 2017, 14(5): 269-278.

36. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther, 2014 Jun, 39(12): 1349-62.

37. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther, 2014 Apr, 39(7): 660-71.

38. Gisbert JP, Marín AC, Chaparro M. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol, 2016, 111(5): 632-47.

39. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol, 2013 Aug, 108(8): 1268-76.

40. Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol, 2017 Oct, 10(10): 773-790.

41. Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res, 2013 Oct, 76: 1-8.

42. Roskoski R. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res, 2016, 111: 784–803.

43. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev, 2009, 228: 273–287.

44. Sandborn WJ, Sands BE, D’Haens G, et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. ECCO 2016: OP019.

45. Paschos P, Katsoula A, Giouleme O, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. ECCO 2017: P662.

46. Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut, 2017 Jun, 66(6): 1049-1059.

47. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet, 2017 Jan 21, 389(10066): 266-275.

48. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets, 2012, 11(2): 159-68.

49. Kawalec P, Moćko P, Malinowska-Lipien I, Brzostek T. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn’s disease patients: a systematic review and meta-analysis. J Comp Eff Res, 2017 Oct, 6(7): 601-612.

50. Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther, 2014, 14(5): 583-600.

51. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology, 2012, 20(1): 1-18.

52. Zundler S, Becker E, Weidinger C, Siegmund B. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects. Front Immunol, 2017 Jul 28, 8: 891.

53. Bamias G, Clark DJ, Rivera-Nieves J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr Drug Targets, 2013, 14(12): 1490-500.

54. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell, 1993, 74: 185–195.

55. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol, 1997, 151: 97–110.

56. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol, 2006, 6: 244–251.

57. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med, 2003, 348(1): 24-32.

58. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology, 2007 May, 132(5): 1672-83.

59. Sakuraba A, Keyashian K, Correia C, et al. Natalizumab in Crohn’s disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis, 2013, 19(3): 621-6.

60. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med, 2005 Jul 28, 353(4): 362-8.

61. Toussirot É, Bereau M. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases. Inflamm Allergy Drug Targets, 2014, 13(2): 121-7.

62. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther, 2009, 330: 864-875.

63. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2013 Aug 22, 369(8): 699-710.

64. Loftus EV Jr, Colombel JF, Feagan BG, et al. Longterm Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis, 2017 Apr 1, 11(4): 400-411.

65. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med, 2013 Aug 22, 369(8): 711-21.

66. Vermeire S, Loftus EV Jr, Colombel JF, et al. Longterm Efficacy of Vedolizumab for Crohn’s Disease. J Crohns Colitis, 2017 Apr 1, 11(4): 412-424.

67. Shelton E, Allegretti JR, Stevens B, et al. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis, 2015, 21(12): 2879-85.

68. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut, 2017 May, 66(5): 839-851.